Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- Drug: Bronchoalveolar Lavage and Local Amikacin Injection
- Registration Number
- NCT02509091
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Brief Summary
The therapy of bronchoalveolar lavage and local amikacin injection as one of the treatment of bronchiectasis developed in recent years.this study is aim to evaluate the Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients with Acute Exacerbation of Bronchiectasis.
- Detailed Description
The aim of this study was to evaluate the efficacy and safety of The therapy of bronchoalveolar lavage and local amikacin injection through the observation of a large sample of clinical cases. During the observation, study visits will occur at the end of 30days, 60days, 90days.all the participants will be required to check the various efficacy and safety indicators.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Age≥18 years and ≤80 years;
- Patients with non-cystic fibrosis bronchiectasis diagnosed by high-resolution CT;
- Are sensitive to amikacin;
- Acute exacerbation of bronchiectasis;
- Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc;
- Willing to join in and sign the informed consent form.
- Active bleeding without control；
- Receiving nasal or facial surgery recently；
- With severe cardio-pulmonary dysfunction, such as left heart failure, unstable arrhythmia, etc.
- With other respiratory diseases: such as active pulmonary tuberculosis, non-tuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis, etc.
- Be allergic to amikacin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description The experimental group Bronchoalveolar Lavage and Local Amikacin Injection fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
- Primary Outcome Measures
Name Time Method Improvement of Sputum volume and properties 90 days Phlegm improvement will be measured by the reduction of the sputum volume and change of sputum properties in the first day,in admission,the first day before,in and after doing bronchoscopy ,the day in discharge and in 30 days/60 days/90 days
- Secondary Outcome Measures
Name Time Method changes in lung function (including Forced expiratory volume in one second (FEV1) ,forced vital capacity(FVC) and forced vital capacity rate of one second(FEV1/FVC)) 90 days Lung function will be measured as improved/stabilized/exacerbated from baseline to 30 days/60 days/90 days
Dyspnea score according by Modified Medical Research Center(MMRC) 90 days to measure rating dyspnea according by Medi Medical Research Center(MMRC) from baseline to 30 days/60 days/90 days
Cough score according by Leicester Cough Questionnaire(LCQ) 90 days to measure rating cough according by Leicester Cough Questionnaire(LCQ) from baseline to 30 days/60 days/90 days
Life quality: assessed by St. George respiratory questionnaire (SGRQ) 90 days Life quality will be assessed as improved if SGRQ single or total score increased \>4% when completing the trial; stabilized if SGRQ single or total score changes within the range of 4% when completing the trial; exacerbated if SGRQ single or total score decreased \>4% when completing the trial from baseline to 30 days/60 days/90 days
Trial Locations
- Locations (1)
Shanghai Pulmonary Hospital
🇨🇳Shanghai, Shanghai, China